(Q38508938)

3 September 2017

1 reference

title

Cardiotoxicity due to Chemotherapy: the Role of Biomarkers (English)

1 reference

3 September 2017

0 references

1 reference

Patrick L Stevens

1

1 reference

PubMed ID

26026994

3 September 2017

Daniel J Lenihan

series ordinal

2

1 reference

3 September 2017

1 July 2015

1 reference

Current cardiology reports

3 September 2017

1 reference

3 September 2017

17

1 reference

3 September 2017

7

1 reference

3 September 2017

603

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-015-0603-y

3 September 2017

0 references

cites work

Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cancer genetics and the cardiotoxicity of the therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Elevated B-type natriuretic peptide levels after anthracycline administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Early detection and prediction of cardiotoxicity in chemotherapy-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiac biomarkers, cardiotoxicity, and active collaboration: is this the final frontier or the wave we should catch?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Immunoglobulin light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Use of myeloperoxidase for risk stratification in acute heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Cardiotoxicity of Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0603-Y

Monitoring for anthracycline cardiotoxicity.

21 January 2018

1 reference

12 December 2020

The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated

1 reference

12 December 2020

Unexpected cardiotoxicity in haematological bortezomib treated patients

1 reference

12 December 2020

Assessment of anthracycline-induced cardiotoxicity with biochemical markers.

1 reference

12 December 2020

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

1 reference

12 December 2020

Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy

1 reference

12 December 2020

Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation?

1 reference

12 December 2020

Temporal Changes in Standard and Tissue Doppler Imaging Echocardiographic Parameters After Anthracycline Chemotherapy in Women With Breast Cancer

1 reference

12 December 2020

Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma

1 reference

12 December 2020

Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T

1 reference

12 December 2020

ERBB2 inhibition and heart failure

1 reference

12 December 2020

High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis

1 reference

12 December 2020

The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting

1 reference

12 December 2020

Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults

1 reference

12 December 2020

Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events

1 reference

12 December 2020

Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines

1 reference

12 December 2020

High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure

1 reference

12 December 2020

Cancer statistics, 2014

1 reference

12 December 2020

cTnT can be a useful marker for early detection of anthracycline cardiotoxicity

1 reference

12 December 2020

Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes

1 reference

12 December 2020

10.1007/S11886-015-0603-Y

Identifiers

DOI

1 reference

PubMed ID

26026994

Dimensions Publication ID

3 September 2017

0 references

1 reference

PubMed ID

26026994